Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umeclidinium/Vilanterol in COPD and Heart Failure
NCT04522596Phase 4Completed
- Start
- May 2021
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of umeclidinium, vilanterol in chronic obstructive pulmonary disease (COPD), heart failure (HF). Started May 2021; status: completed.
02
Drugs
umeclidiniumvilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)heart failure (HF)
Beyond the preview
Go deeper on NCT04522596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04522596.